Clinical Trial Detail

NCT ID NCT02665650
Title Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Affimed GmbH
Indications

Hodgkin's lymphoma

Therapies

AFM13 + Pembrolizumab

Age Groups: adult

Additional content available in CKB BOOST